Shares of Microbot Medical Inc. (NASDAQ:MBOT) saw unusually-high trading volume on Friday . Approximately 11,454,209 shares traded hands during trading, an increase of 1,122% from the previous session’s volume of 937,494 shares.The stock last traded at $1.21 and had previously closed at $1.05.
Separately, ValuEngine upgraded Microbot Medical from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd.
The firm’s market cap is $53.29 million. The firm has a 50-day moving average of $1.11 and a 200-day moving average of $3.15.
Microbot Medical (NASDAQ:MBOT) last released its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.44. Equities research analysts predict that Microbot Medical Inc. will post ($25.02) EPS for the current year.
In other news, Director Yoseph Bornstein sold 45,610 shares of the stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $1.01, for a total transaction of $46,066.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 31.83% of the stock is owned by corporate insiders.
An institutional investor recently raised its position in Microbot Medical stock. Vanguard Group Inc. lifted its stake in shares of Microbot Medical Inc. (NASDAQ:MBOT) by 252.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 159,992 shares of the biotechnology company’s stock after purchasing an additional 114,561 shares during the quarter. Vanguard Group Inc. owned about 0.43% of Microbot Medical worth $228,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 4.72% of the company’s stock.
Microbot Medical Company Profile
Microbot Medical Inc, formerly StemCells, Inc, is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures.
Receive News & Ratings for Microbot Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.